As expected, DYRK1A inhibition resulted in potent ERK hyperphosphorylation in all tested KMT2A-R ALL cell lines with activated ERK signaling at a steady state, while trametinib inhibited ERK signaling. This evidence concerns the gene DYRK1A and acute lymphoblastic leukemia.